327 related articles for article (PubMed ID: 31791942)
1. Inhibiting Fungal Echinocandin Resistance by Small-Molecule Disruption of Geranylgeranyltransferase Type I Activity.
Sun Q; Xiong K; Yuan Y; Yu J; Yang L; Shen C; Su C; Lu Y
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791942
[TBL] [Abstract][Full Text] [Related]
2. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
[TBL] [Abstract][Full Text] [Related]
4. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Aug; 57(8):3528-35. PubMed ID: 23669387
[TBL] [Abstract][Full Text] [Related]
5. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.
Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013
[No Abstract] [Full Text] [Related]
6. Echinocandin Resistance in Candida.
Perlin DS
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S612-7. PubMed ID: 26567278
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous Mutational Frequency and
Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
[TBL] [Abstract][Full Text] [Related]
8. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Shields RK; Nguyen MH; Press EG; Kwa AL; Cheng S; Du C; Clancy CJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4862-9. PubMed ID: 22751546
[TBL] [Abstract][Full Text] [Related]
9. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
10. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
11. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.
Locke JB; Almaguer AL; Zuill DE; Bartizal K
Antimicrob Agents Chemother; 2016 Oct; 60(10):6100-7. PubMed ID: 27480852
[TBL] [Abstract][Full Text] [Related]
12. The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination.
Healey KR; Nagasaki Y; Zimmerman M; Kordalewska M; Park S; Zhao Y; Perlin DS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971865
[No Abstract] [Full Text] [Related]
13. Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance.
Papp C; Kocsis K; Tóth R; Bodai L; Willis JR; Ksiezopolska E; Lozoya-Pérez NE; Vágvölgyi C; Mora Montes H; Gabaldón T; Nosanchuk JD; Gácser A
mSphere; 2018 Nov; 3(6):. PubMed ID: 30429225
[No Abstract] [Full Text] [Related]
14. Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.
Lepak AJ; Zhao M; VanScoy B; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203480
[TBL] [Abstract][Full Text] [Related]
15. Decreased echinocandin susceptibility in
Ning Y; Xiao M; Perlin DS; Zhao Y; Lu M; Li Y; Luo Z; Dai R; Li S; Xu J; Liu L; He H; Liu Y; Li F; Guo Y; Chen Z; Xu Y; Sun T; Zhang L
Emerg Microbes Infect; 2023 Dec; 12(1):2153086. PubMed ID: 36440795
[No Abstract] [Full Text] [Related]
16. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
17. Echinocandin Susceptibility Profile of Fluconazole Resistant Candida Species Isolated from Blood Stream Infections.
Deorukhkar SC; Saini S
Infect Disord Drug Targets; 2016; 16(1):63-8. PubMed ID: 26648186
[TBL] [Abstract][Full Text] [Related]
18. Clinical perspectives on echinocandin resistance among Candida species.
Shields RK; Nguyen MH; Clancy CJ
Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of echinocandin antifungal drug resistance.
Perlin DS
Ann N Y Acad Sci; 2015 Sep; 1354(1):1-11. PubMed ID: 26190298
[TBL] [Abstract][Full Text] [Related]
20. Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China.
Li Y; Hou X; Li R; Liao K; Ma L; Wang X; Ji P; Kong H; Xia Y; Ding H; Kang W; Zhang G; Li J; Xiao M; Li Y; Xu Y
BMC Microbiol; 2023 Nov; 23(1):341. PubMed ID: 37974063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
